These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 14968443)

  • 61. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
    Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
    Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
    Thong AE; Shikanov S; Katz MH; Gofrit ON; Eggener S; Zagaja GP; Shalhav AL; Zorn KC
    J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Radical retropubic prostatectomy in men younger than 45 years diagnosed during early prostate cancer detection program.
    Varkarakis J; Pinggera GM; Sebe P; Berger A; Bartsch G; Horninger W
    Urology; 2004 Feb; 63(2):337-41. PubMed ID: 14972485
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
    Zissimopoulos A; Bantis A; Sountoulides P; Giannakopoulos S; Kalaitzis C; Agelonidou E; Touloupidis S
    Hell J Nucl Med; 2009; 12(3):234-7. PubMed ID: 19936334
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
    Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Circulating chromogranin a and hormone refractory prostate cancer chemotherapy.
    Cabrespine A; Guy L; Gachon F; Curé H; Chollet P; Bay JO
    J Urol; 2006 Apr; 175(4):1347-52. PubMed ID: 16515996
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Does prostate biopsy Gleason score accurately express the biologic features of prostate cancer?
    Stav K; Judith S; Merald H; Leibovici D; Lindner A; Zisman A
    Urol Oncol; 2007; 25(5):383-6. PubMed ID: 17826654
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy.
    Antunes AA; Srougi M; Dall'Oglio MF; Crippa A; Campagnari JC; Leite KR
    BJU Int; 2005 Dec; 96(9):1258-63. PubMed ID: 16287441
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
    Zaky Ahel M; Kovacic K; Kraljic I; Tarle M
    Anticancer Res; 2001; 21(2B):1475-9. PubMed ID: 11396235
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population?
    Anast JW; Andriole GL; Bismar TA; Yan Y; Humphrey PA
    Urology; 2004 Sep; 64(3):544-50. PubMed ID: 15351590
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer.
    Briganti A; Chun FK; Salonia A; Gallina A; Farina E; Da Pozzo LF; Rigatti P; Montorsi F; Karakiewicz PI
    BJU Int; 2006 Oct; 98(4):788-93. PubMed ID: 16796698
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Value of free PSA/total PSA ratio in therapeutic decisions in the case of a single positive biopsy of the prostate].
    Huyghe E; Soulie M; Tollon C; Escourrou G; Pontonnier F; Plante P
    Prog Urol; 1999 Apr; 9(2):281-7. PubMed ID: 10370952
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy.
    Oefelein MG; Kaul K; Herz B; Blum MD; Holland JM; Keeler TC; Cook WA; Ignatoff JM
    J Urol; 1996 Jan; 155(1):238-42. PubMed ID: 7490843
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Plasma chromogranin A in patients with prostate cancer improves the diagnostic efficacy of free/total prostate-specific antigen determination.
    Fracalanza S; Prayer-Galetti T; Pinto F; Navaglia F; Sacco E; Ciaccia M; Plebani M; Pagano F; Basso D
    Urol Int; 2005; 75(1):57-61. PubMed ID: 16037709
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence.
    Mejean A; Vona G; Nalpas B; Damotte D; Brousse N; Chretien Y; Dufour B; Lacour B; Bréchot C; Paterlini-Bréchot P
    J Urol; 2000 Jun; 163(6):2022-9. PubMed ID: 10799250
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Single small focus of prostate adenocarcinoma (< or = 1 mm and too small for grading) and clinical significant disease after radical prostatectomy.
    Taverna G; Colombo P; Seveso M; Giusti G; Piccinelli A; Benetti A; Graziotti P
    Arch Ital Urol Androl; 2006 Jun; 78(2):57-60. PubMed ID: 16929604
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Assessment of the Gleason score in biopsies and specimens of radical prostatectomy].
    Rodríguez Faba O; Fernández Gómez JM; Guate Ortíz JL; Martín Benito JL; Pérez García FJ; García Rodríguez J; Jalón Monzón A; Regadera Sejas J
    Arch Esp Urol; 2003 Sep; 56(7):781-4. PubMed ID: 14595881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.